Publication:
Clinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors

dc.contributor.coauthorSelcukbiricik, Fatih
dc.contributor.coauthorKanitez, Metin
dc.contributor.coauthorYalçın, Suayip
dc.contributor.coauthorTural, Deniz
dc.contributor.coauthorErdamar, Sibel
dc.contributor.coauthorDogusoy, Gulen
dc.contributor.coauthorDemir, Gokhan
dc.contributor.departmentN/A
dc.contributor.kuauthorMandel, Nil Molinas
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid194197
dc.date.accessioned2024-11-09T23:26:54Z
dc.date.issued2016
dc.description.abstractPurpose: Gastrointestinal stromal tumors (GISTs) are common tumors of the gastrointestinal tract. Their most frequent location is the stomach. Although the clinical and pathological characteristics of the disease are well-known, the clinical and pathological characteristics and the response to treatment are not clear in elderly patients. The purpose of this study was to evaluate the characteristics of GISTs in elderly patients with an aim at improving the therapeutic methodology and survival. Methods: In this study, clinicopathological characteristics, evaluation of treatments administered and survival analyses were performed in patients aged 65 years or above, whose data were registered via a web-based patient records system following admission to three centers. Results: A total of 85 patients aged 65 years or above were included in the study. According to the risk classification, 24 (28.2%) were in the low risk group, 20 (23.5%) in the moderate risk group, and 41 (48.3%) in high risk group, while no patient was in the very low risk group. At baseline, 70% of the patients had localized disease and 30% metastatic disease. The tumor was located in the stomach in the majority of the patients (45.6%). The tumor size most commonly seen was 5-10 cm (N=31; 36.4%). of the 85 patients 23 (27%) were treated with imatinib 400 mg/d. Eight patients (9.4%) with metastatic disease switched from imatinib to sunitinib. At a median follow-up of 76 months (range 1-323), median overall survival (OS) was 72 months, without significant difference between elderly and younger patients. Conclusion: Clinicopathological characteristics and their prognostic impact on the disease course of elderly GIST patients should be elucidated in depth. Since age didn't show prognostic importance, other parameters should be used as prognostic/predictive factors in the tyrosine kinase inhibitors era in order to obtain improved therapeutic results.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume21
dc.identifier.doiN/A
dc.identifier.eissn2241-6293
dc.identifier.issn1107-0625
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-84976466881
dc.identifier.uriN/A
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11628
dc.identifier.wos376829900010
dc.keywordsGastrointestinal stromal tumor
dc.keywordsImatinib
dc.keywordsOld age
dc.keywordsSurvival
dc.keywordsTreatment
dc.languageEnglish
dc.publisherImprimatur Publications
dc.sourceJournal of Buon
dc.subjectOncology
dc.titleClinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-8837-0756
local.contributor.kuauthorMandel, Nil Molinas

Files